Illio,
The glory days of everything biotech are over
The market now actually wants to see revenue and not just blue sky
Until announcements actually refer to revenue and not the endless " we are looking at opportunities'', the share price will do nothing
On a pre- consolidation basis, SBN is effectively trading at 0.0005c a share...and this after about 10 years
Ann: Initial Oraline Product Run Completed , page-11
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
